
Marilena Cesari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7901771/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 2 study for nonmetastatic extremity highâ€grade osteosarcoma in pediatric and adolescent and young adult patients with a riskâ€adapted strategy based on ABCB1/Pâ€glycoprotein expression: An Italian Sarcoma Group trial (ISG/OSâ€2). Cancer, 2022, 128, 1958-1966.	2.0	12
2	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunology, Immunotherapy, 2021, 70, 2617-2624.	2.0	45
3	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. Sarcoma, 2020, 2020, 1-9.	0.7	5
4	ls there a role for chemotherapy after local relapse in highâ€grade osteosarcoma?. Pediatric Blood and Cancer, 2019, 66, e27792.	0.8	19
5	Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. Pediatric Blood and Cancer, 2019, 66, e27653.	0.8	19
6	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncológica, 2019, 58, 124-128.	0.8	50
7	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplantation, 2018, 53, 591-599.	1.3	8
8	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori, 2018, 104, 30-36.	0.6	84
9	lrinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncológica, 2018, 57, 958-964.	0.8	41
10	Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori, 2018, 104, 202-206.	0.6	14
11	Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results. Tumori, 2018, 104, 344-351.	0.6	41
12	Osteosarcoma follow-up: chest X-ray or computed tomography?. Clinical Sarcoma Research, 2017, 7, 3.	2.3	17
13	Survival after Second and Subsequent Recurrences in Osteosarcoma: A Retrospective Multicenter Analysis. Tumori, 2017, , tj.5000636.	0.6	7
14	Ewing Sarcoma in Patients over 40 Years of Age: A Prospective Analysis of 31 Patients Treated at a Single Institution. Tumori, 2016, 102, 481-487.	0.6	13
15	Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer, 2016, 16, 280.	1.1	71
16	Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. European Journal of Cancer, 2015, 51, 374-381.	1.3	133
17	Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. Journal of Chemotherapy, 2014, 26, 49-56.	0.7	10
18	Primary Angiosarcoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 528-534.	0.6	34

MARILENA CESARI

#	Article	IF	CITATIONS
19	Analysis of Risk Factors for Central Venous Catheter–Related Complications. Cancer Nursing, 2014, 37, 292-298.	0.7	6
20	Periosteal osteosarcoma. Cancer, 2011, 117, 1731-1735.	2.0	60
21	Vincristine, Doxorubicin, Cyclophosfamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study. Tumori, 2010, 96, 213-218.	0.6	15
22	Sex- and Age-Related Chemotherapy Toxicity in Patients with Non-Metastatic Osteosarcoma. Journal of Chemotherapy, 2009, 21, 205-210.	0.7	25
23	Mesenchymal Chondrosarcoma. An Analysis of Patients Treated at a Single Institution. Tumori, 2007, 93, 423-427.	0.6	106
24	Predictive Factors of Histologic Response to Primary Chemotherapy in Patients With Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2007, 29, 364-368.	0.3	29
25	Late Relapse in Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2006, 28, 418-422.	0.3	32
26	Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy. Cancer, 2006, 106, 2701-2706.	2.0	61
27	Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. Anti-Cancer Drugs, 2005, 16, 733-738.	0.7	20
28	Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Annals of Oncology, 2003, 14, 1365-1372.	0.6	25
29	Predictive factors for local recurrence in osteosarcoma 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthopaedica, 1998, 69, 230-236.	1.4	134
30	Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th Study. Acta Oncológica, 1998, 37, 41-48.	0.8	78
31	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. Acta Oncológica, 1998, 37, 671-676.	0.8	19
32	Osteosarcoma of the Extremities with Synchronous Lung Metastases: Long-Term Results in 44 Patients Treated with Neoadjuvant Chemotherapy. Journal of Chemotherapy, 1998, 10, 69-76.	0.7	39
33	Ifosfamide and Actinomycin-D, Added in the Induction Phase to Vincristine, Cyclophosphamide and Doxorubicin, Improve Histologic Response and Prognosis in Patients with Non Metastatic Ewing's Sarcoma of the Extremity. Journal of Chemotherapy, 1998, 10, 484-491.	0.7	28
34	Neoadjuvant Chemotherapy for Osseous Malignant Fibrous Histiocytoma of the Extremity: Results in 18 Cases and Comparison with 112 Contemporary Osteosarcoma Patients Treated with the Same Chemotherapy Regimen. Journal of Chemotherapy, 1997, 9, 293-299.	0.7	17
35	Ostenonecrosis of the jaw (ONJ) after denosumab in patients with giant cell tumor of bone (GCTB):Â a single institution analysis of Âa prospective, international study 20062004. Qeios, 0, , .	0.0	0